vs
Side-by-side financial comparison of loanDepot, Inc. (LDI) and Bio-Techne (TECH). Click either name above to swap in a different company.
loanDepot, Inc. is the larger business by last-quarter revenue ($310.3M vs $295.9M, roughly 1.0× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs -7.2%, a 20.1% gap on every dollar of revenue. On growth, loanDepot, Inc. posted the faster year-over-year revenue change (20.5% vs -6.4%). Over the past eight quarters, loanDepot, Inc.'s revenue compounded faster (18.0% CAGR vs 4.2%).
LoanDepot, sometimes stylized as loanDepot, is an Irvine, California-based nonbank holding company which sells mortgage and non-mortgage lending products.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
LDI vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $310.3M | $295.9M |
| Net Profit | $-22.5M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | -10.3% | 18.4% |
| Net Margin | -7.2% | 12.8% |
| Revenue YoY | 20.5% | -6.4% |
| Net Profit YoY | 32.4% | 68.3% |
| EPS (diluted) | — | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $310.3M | $295.9M | ||
| Q3 25 | $323.3M | — | ||
| Q2 25 | $282.5M | $317.0M | ||
| Q1 25 | $273.6M | $316.2M | ||
| Q4 24 | $257.5M | $297.0M | ||
| Q3 24 | $314.6M | $289.5M | ||
| Q2 24 | $265.4M | $306.1M | ||
| Q1 24 | $222.8M | $303.4M |
| Q4 25 | $-22.5M | $38.0M | ||
| Q3 25 | $-4.9M | — | ||
| Q2 25 | $-13.4M | $-17.7M | ||
| Q1 25 | $-21.9M | $22.6M | ||
| Q4 24 | $-33.2M | $34.9M | ||
| Q3 24 | $1.4M | $33.6M | ||
| Q2 24 | $-32.2M | $40.6M | ||
| Q1 24 | $-34.3M | $49.1M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% |
| Q4 25 | -10.3% | 18.4% | ||
| Q3 25 | -3.2% | — | ||
| Q2 25 | -11.4% | -7.5% | ||
| Q1 25 | -16.8% | 12.2% | ||
| Q4 24 | -32.7% | 16.0% | ||
| Q3 24 | 1.1% | 13.8% | ||
| Q2 24 | -29.1% | 15.0% | ||
| Q1 24 | -38.2% | 22.1% |
| Q4 25 | -7.2% | 12.8% | ||
| Q3 25 | -1.5% | — | ||
| Q2 25 | -4.7% | -5.6% | ||
| Q1 25 | -8.0% | 7.1% | ||
| Q4 24 | -12.9% | 11.7% | ||
| Q3 24 | 0.4% | 11.6% | ||
| Q2 24 | -12.1% | 13.3% | ||
| Q1 24 | -15.4% | 16.2% |
| Q4 25 | — | $0.24 | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $0.14 | ||
| Q4 24 | — | $0.22 | ||
| Q3 24 | $0.01 | $0.21 | ||
| Q2 24 | $-0.18 | $0.26 | ||
| Q1 24 | $-0.19 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $337.2M | $172.9M |
| Total DebtLower is stronger | $2.1B | $260.0M |
| Stockholders' EquityBook value | $386.0M | $2.0B |
| Total Assets | $6.9B | $2.5B |
| Debt / EquityLower = less leverage | 5.44× | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $337.2M | $172.9M | ||
| Q3 25 | $459.2M | — | ||
| Q2 25 | $408.6M | $162.2M | ||
| Q1 25 | $371.5M | $140.7M | ||
| Q4 24 | $421.6M | $177.5M | ||
| Q3 24 | $483.0M | $187.5M | ||
| Q2 24 | $533.2M | $152.9M | ||
| Q1 24 | $603.7M | $145.3M |
| Q4 25 | $2.1B | $260.0M | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $2.1B | $346.0M | ||
| Q1 25 | $2.0B | $330.0M | ||
| Q4 24 | $2.0B | $300.0M | ||
| Q3 24 | $2.0B | $300.0M | ||
| Q2 24 | $2.0B | $319.0M | ||
| Q1 24 | $2.3B | $389.0M |
| Q4 25 | $386.0M | $2.0B | ||
| Q3 25 | $433.3M | — | ||
| Q2 25 | $439.1M | $1.9B | ||
| Q1 25 | $469.3M | $2.0B | ||
| Q4 24 | $506.6M | $2.1B | ||
| Q3 24 | $592.0M | $2.1B | ||
| Q2 24 | $578.9M | $2.1B | ||
| Q1 24 | $637.3M | $2.0B |
| Q4 25 | $6.9B | $2.5B | ||
| Q3 25 | $6.2B | — | ||
| Q2 25 | $6.2B | $2.6B | ||
| Q1 25 | $6.4B | $2.6B | ||
| Q4 24 | $6.3B | $2.7B | ||
| Q3 24 | $6.4B | $2.7B | ||
| Q2 24 | $5.9B | $2.7B | ||
| Q1 24 | $6.2B | $2.7B |
| Q4 25 | 5.44× | 0.13× | ||
| Q3 25 | 4.83× | — | ||
| Q2 25 | 4.70× | 0.18× | ||
| Q1 25 | 4.30× | 0.16× | ||
| Q4 24 | 4.00× | 0.14× | ||
| Q3 24 | 3.31× | 0.14× | ||
| Q2 24 | 3.41× | 0.15× | ||
| Q1 24 | 3.63× | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-638.7M | — |
| Free Cash FlowOCF − Capex | $-648.0M | — |
| FCF MarginFCF / Revenue | -208.9% | — |
| Capex IntensityCapex / Revenue | 3.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-734.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-638.7M | — | ||
| Q3 25 | $43.4M | — | ||
| Q2 25 | $67.6M | $98.2M | ||
| Q1 25 | $-179.9M | $41.1M | ||
| Q4 24 | $47.7M | $84.3M | ||
| Q3 24 | $-349.2M | $63.9M | ||
| Q2 24 | $-278.3M | $75.5M | ||
| Q1 24 | $-278.5M | $81.0M |
| Q4 25 | $-648.0M | — | ||
| Q3 25 | $38.7M | — | ||
| Q2 25 | $61.4M | $93.3M | ||
| Q1 25 | $-186.7M | $31.0M | ||
| Q4 24 | $40.8M | $77.5M | ||
| Q3 24 | $-356.4M | $54.7M | ||
| Q2 24 | $-285.7M | $57.5M | ||
| Q1 24 | $-283.3M | $64.5M |
| Q4 25 | -208.9% | — | ||
| Q3 25 | 12.0% | — | ||
| Q2 25 | 21.7% | 29.4% | ||
| Q1 25 | -68.2% | 9.8% | ||
| Q4 24 | 15.8% | 26.1% | ||
| Q3 24 | -113.3% | 18.9% | ||
| Q2 24 | -107.7% | 18.8% | ||
| Q1 24 | -127.2% | 21.3% |
| Q4 25 | 3.0% | — | ||
| Q3 25 | 1.5% | — | ||
| Q2 25 | 2.2% | 1.5% | ||
| Q1 25 | 2.5% | 3.2% | ||
| Q4 24 | 2.7% | 2.3% | ||
| Q3 24 | 2.3% | 3.2% | ||
| Q2 24 | 2.8% | 5.9% | ||
| Q1 24 | 2.1% | 5.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | -255.05× | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LDI
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
